Press release
Graft-Versus-Host Disease Market is expected to Grow During the Forecast Period (2023-2032), Analyzes DelveInsight | CSL Behring, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics, Novartis, Biogen
Graft-Versus-Host Disease Market
To Know in detail about the Graft-Versus-Host Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graft-Versus-Host Disease Market Forecast
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of the Graft-Versus-Host Disease Market Report:
• The Graft-Versus-Host Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2022, the overall instances of Graft-versus-host disease (GvHD) in the seven major markets (7MM) amounted to approximately 51,540 cases. Among these, the United States recorded the greatest number of GvHD cases, reaching approximately 23,150 cases in 2022. Projections indicate an anticipated increase in these numbers throughout the study period spanning from 2019 to 2032.
• Within the seven major markets (7MM), the reported incidents of acute Graft-versus-host disease (GvHD) were approximately 10,340 cases, while the five-year prevalence of chronic GvHD was estimated to be around 23,080 in 2022. These figures are anticipated to rise by the year 2032.
• In 2022, the United States recorded approximately 24,510 cases of hematopoietic stem-cell transplantation and around 10,260 cases of allogeneic transplantation. These numbers are projected to rise by the year 2032.
• According to HRSA (2022), the projected yearly count of allogeneic transplant recipients in the United States exceeded 8,000 annually in 2013. By 2019, the estimate rose to 9,498 transplants, following a slight decrease from 9,509 in 2018.
• Key Graft-Versus-Host Disease Companies: CSL Behring, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others
• Key Graft-Versus-Host Disease Therapies: CSL 964 AAT (zemaira), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal®, Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others
• In the United States in 2022, roughly 4,780 cases of acute Graft-versus-host disease (aGvHD) and approximately 17,210 cases of chronic Graft-versus-host disease (cGvHD) received first-line treatment. Projections suggest an anticipated increase in these cases by the year 2032.
• The Graft-Versus-Host Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graft-Versus-Host Disease pipeline products will significantly revolutionize the Graft-Versus-Host Disease market dynamics.
Graft-Versus-Host Disease Overview
Graft-versus-host disease (GvHD) is an immune-related disorder that arises when T cells from the donor (known as graft or graft cells) attack the healthy tissues of the recipient patient host following transplant procedures, particularly seen after an allogeneic bone marrow transplant (also known as stem cell transplantation). This condition occurs as a common side effect of the transplantation process.
Get a Free sample for the Graft-Versus-Host Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Graft-Versus-Host Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Graft-Versus-Host Disease Epidemiology Segmentation:
The Graft-Versus-Host Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Graft-Versus-Host Disease
• Prevalent Cases of Graft-Versus-Host Disease by severity
• Gender-specific Prevalence of Graft-Versus-Host Disease
• Diagnosed Cases of Episodic and Chronic Graft-Versus-Host Disease
Download the report to understand which factors are driving Graft-Versus-Host Disease epidemiology trends @ Graft-Versus-Host Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Graft-Versus-Host Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graft-Versus-Host Disease market or expected to get launched during the study period. The analysis covers Graft-Versus-Host Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Graft-Versus-Host Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Graft-Versus-Host Disease Therapies and Key Companies
• CSL 964 AAT (zemaira): CSL Behring
• MaaT013: MaaT Pharma
• RGI-2001: Regimmune
• Defibrotide: Jazz Pharmaceuticals
• Ibrutinib: Pharmacyclics LLC.
• Panobinostat (LBH589): Novartis
• Natalizumab: Biogen
• Methoxsalen: Mallinckrodt
• Prograf: Astellas Pharma
• Prochymal®: Mesoblast, Inc.
• Abatacept: Thrasher Research Fund
• RGI-2001: Regimmune Corporation
• Axatilimab: Syndax Pharmaceutical
• Ruxolitinib: Novartis
Discover more about therapies set to grab major Graft-Versus-Host Disease market share @ Graft-Versus-Host Disease Treatment Landscape
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Graft-Versus-Host Disease Market Strengths
• Pipeline of GvHD is very robust and several late stage assets are expected to enter in to the market very soon. GvHD pipeline consists of small molecules, monoclonal and Bi-specific antibody, stem cell therapy, recombinant fusion protein etc. which will provide the patients and physicians more options in future.
Graft-Versus-Host Disease Market Opportunities
• Several upcoming therapies have received Orphan designations, therapies can get accelerated approval time, 7 years of market exclusivity in the US, clinical trials subsidies and reduced regulatory fees and others. Company can also go for premium pricing as well.
Scope of the Graft-Versus-Host Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Graft-Versus-Host Disease Companies: CSL Behring, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others
• Key Graft-Versus-Host Disease Therapies: CSL 964 AAT (zemaira), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal®, Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others
• Graft-Versus-Host Disease Therapeutic Assessment: Graft-Versus-Host Disease current marketed and Graft-Versus-Host Disease emerging therapies
• Graft-Versus-Host Disease Market Dynamics: Graft-Versus-Host Disease market drivers and Graft-Versus-Host Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Graft-Versus-Host Disease Unmet Needs, KOL's views, Analyst's views, Graft-Versus-Host Disease Market Access and Reimbursement
To know more about Graft-Versus-Host Disease companies working in the treatment market, visit @ Graft-Versus-Host Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Graft-Versus-Host Disease Market Report Introduction
2. Executive Summary for Graft-Versus-Host Disease
3. SWOT analysis of Graft-Versus-Host Disease
4. Graft-Versus-Host Disease Patient Share (%) Overview at a Glance
5. Graft-Versus-Host Disease Market Overview at a Glance
6. Graft-Versus-Host Disease Disease Background and Overview
7. Graft-Versus-Host Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Graft-Versus-Host Disease
9. Graft-Versus-Host Disease Current Treatment and Medical Practices
10. Graft-Versus-Host Disease Unmet Needs
11. Graft-Versus-Host Disease Emerging Therapies
12. Graft-Versus-Host Disease Market Outlook
13. Country-Wise Graft-Versus-Host Disease Market Analysis (2019-2032)
14. Graft-Versus-Host Disease Market Access and Reimbursement of Therapies
15. Graft-Versus-Host Disease Market Drivers
16. Graft-Versus-Host Disease Market Barriers
17. Graft-Versus-Host Disease Appendix
18. Graft-Versus-Host Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-neoplasms-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/carcinoid-tumor-market
• Cluster Headache Market: https://www.delveinsight.com/report-store/cluster-headache-market
• Condyloma Market: https://www.delveinsight.com/report-store/condyloma-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/rhino-conjunctivitis-market
• Ventilator Market: https://www.delveinsight.com/report-store/ventilators-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pharmaceutical Consulting Companies: https://www.delveinsight.com/consulting
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Biotech Consulting: https://www.delveinsight.com/consulting
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Pruritus Market: https://www.delveinsight.com/report-store/cholestatic-pruritus-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
Contact Us:
Ankit Nigam
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graft-Versus-Host Disease Market is expected to Grow During the Forecast Period (2023-2032), Analyzes DelveInsight | CSL Behring, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics, Novartis, Biogen here
News-ID: 3476728 • Views: …
More Releases from DelveInsight Business Research
Head and Neck Cancer Pipeline Assessment (2024 Updates): EMA, PDMA, FDA Approval …
(New York, USA) DelveInsight's 'Head and Neck Cancer Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline head and neck cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the head and neck cancer pipeline domain.
Request for a free sample report @ https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Head and Neck Cancer Pipeline Report
• DelveInsight's…
Adenoid Cystic Carcinomas Pipeline Assessment (2024 Updates): FDA Approvals, Cli …
(Las Vegas, Nevada, United States)- As per DelveInsight's assessment, globally, about 5+ key Adenoid Cystic Carcinomas companies are working on 5+ pipeline drugs in the Adenoid Cystic Carcinomas therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Adenoid Cystic Carcinomas Pipeline Insight 2024"…
Infliximab Biosimilar Insight 2024: Clinical Trials, FDA Approvals, and Companie …
DelveInsight's "Infliximab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of Biosimilars,…
Wet Age-Related Macular Degeneration Market and Epidemiology 2032: Treatment Mar …
DelveInsight's "Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Wet Age-Related Macular Degeneration market outlook, drug uptake, treatment scenario and epidemiology trends, Click…
More Releases for Disease
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,…
Autoimmune Disease Diagnostic Market By Disease, Tests Type, Regions, Companies
"The Latest Research Report Autoimmune Disease Diagnostic Market, Global Forecast, By Disease, Tests Type, Regions, Companies provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Autoimmune Disease Diagnostic Market is anticipated to exceed US$ 18 Billion, experiencing a significant growth over the forecast period. Autoimmune diseases take place when there is disruption of the usual control process (immune system of the body becomes…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
